恒瑞医药(600276) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 7,205,611,122.72, representing a 20.14% increase compared to CNY 5,997,533,912.14 in the same period last year[4] - Net profit attributable to shareholders was CNY 1,874,055,519.98, a 36.90% increase from CNY 1,368,929,247.85 year-over-year[4] - The basic earnings per share increased by 42.86% to CNY 0.30 from CNY 0.21 in the previous year[4] - Total revenue for Q1 2025 reached ¥7,205,611,122.72, a 20.1% increase from ¥5,997,533,912.14 in Q1 2024[18] - Net profit for Q1 2025 was ¥1,876,441,961.32, up 37.2% compared to ¥1,367,488,687.72 in Q1 2024[19] - Operating profit for Q1 2025 was ¥2,085,980,911.66, an increase from ¥1,636,008,814.62 in Q1 2024[19] - The company reported a total comprehensive income of ¥1,878,788,766.76 for Q1 2025, compared to ¥1,361,563,296.04 in Q1 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 55.75% to CNY 555,174,088.51, down from CNY 1,254,598,909.00 in the same period last year[4] - Cash inflow from operating activities totaled approximately $6.30 billion, compared to$6.14 billion in the previous period, reflecting a slight increase[22] - Net cash flow from operating activities decreased to approximately $555.17 million from$1.25 billion year-over-year[22] - Cash and cash equivalents were ¥24,085,707,596.26 as of March 31, 2025, down from ¥24,815,905,657.75 at the end of 2024[15] - The company reported a cash and cash equivalents balance of approximately $23.63 billion at the end of the period, down from$24.24 billion at the beginning[22] - The company experienced a net decrease in cash and cash equivalents of approximately -$607.94 million, compared to an increase of$467.87 million in the previous period[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 51,292,781,690.91, a 2.31% increase from CNY 50,135,645,304.10 at the end of the previous year[5] - Total assets as of March 31, 2025, were ¥51,292,781,690.91, up from ¥50,135,645,304.10 at the end of 2024[16] - Total liabilities decreased to ¥3,743,012,633.17 from ¥4,045,394,570.79 at the end of 2024[16] Equity and Returns - The weighted average return on equity rose to 4.08%, an increase of 0.75 percentage points from 3.33% in the previous year[4] - The total equity attributable to shareholders increased by 3.22% to CNY 46,987,059,491.08 from CNY 45,519,861,860.32 at the end of the previous year[5] Research and Development - Research and development expenses for Q1 2025 totaled ¥1,533,207,293.28, compared to ¥1,220,126,943.52 in Q1 2024, reflecting a 25.6% increase[18] - The company plans to continue investing in research and development, which has increased in the current period, impacting cash flow[8] - The company plans to continue investing in new product development and market expansion strategies[20] Non-Recurring Items - Non-recurring gains and losses totaled CNY 10,768,928.69 for the period, primarily from government subsidies and asset disposals[7] - The company recognized a significant income of USD 75 million from a licensing agreement with IDEAYA, contributing to the increase in net profit[8] Cash Flow from Investments and Financing - Cash outflow from investment activities resulted in a net cash flow of approximately -$531.68 million, an improvement from -$750.39 million in the previous period[22] - Cash inflow from investment activities was approximately $170.35 million, significantly higher than$10.63 million in the previous period[22] - Total cash outflow from financing activities was approximately $661.06 million, compared to$18.13 million in the previous period[22] - The company received approximately $150 million from the recovery of investments, which was not reported in the previous period[22] - The impact of exchange rate changes on cash and cash equivalents was approximately$29.62 million, compared to a negative impact of -$18.21 million in the previous period[22] - The company paid approximately$1.91 billion to employees, an increase from $1.53 billion in the previous period[22]